Get your movement back
When joint pain and stiffness hold you back from doing the things you love, Flexiseq’s unique drug-free action works only where it’s needed to lubricate joints affected by osteoarthritis and joint wear and tear.
Flexiseq directly treats joint damage, a major symptom of arthritis, to ensure your joint movement is as smooth as possible.
Osteoarthritis pain relief is just a tube of Flexiseq away.
How does Flexiseq work?
Sequessome Technology is the driving force behind Flexiseq. It changes the way we approach osteoarthritis and joint wear and tear to better improve joint movement and relieve the pain of arthritis.
Through its lubricating action, Sequessome Technology offers a unique treatment option for joint pain that is clinically proven to help with osteoarthritis and entirely drug free.
So, which Flexiseq is right for you?
If you have diagnosed osteoarthritis, nothing but the best will do. That’s why Flexiseq Osteoarthritis is loaded with our max strength formulation, tested in clinical trials with the most demanding patients.
Specially designed for your wellness and everyday use, Flexiseq CBD has been extracted from the highest quality hemp plants. No artificial fertilisers, pesticides or GM strains are used in production, our CBD is completely natural & safe to use.
Len Goodman's Mobility Story
Len Goodman, Flexiseq ambassador
“There are over 10 million people with arthritis in the UK and I want to help. I really hope my mobility story inspires other people who have suffered with osteoarthritis to share their own tales.
“Flexiseq genuinely helped me with my arthritis, which is why I was delighted to be asked to be their ambassador. Together we’re on a mission to get people moving. I know I can make a difference and be an inspiration to people suffering joint pain to get moving again."
Our latest blogs
*Tested in Phase III Clinical Trials among mild to moderate osteoarthritis patients, Flexiseq reduced the pain and stiffness associated with osteoarthritis.
Conaghan P, et al. Current Medical Research & Opinion 2013, 1-13